Nipocalimab, Janssen-Cilag International’s investigational FcRn blocker for treating generalized myasthenia gravis (gMG), is among the latest batch of products that the European Medicines Agency has started reviewing for potential pan-EU marketing authorization.
Janssen’s Nipocalimab Among Six New EU Filings
Nipocalimab is an investigational FcRn blocker for treating generalized myasthenia gravis that was also recently filed for regulatory review in the US.
More from Europe
More from Geography
• By
The forced departure of CBER Director Peter Marks is a milestone event for the agency, as center directors now are likely to be treated as political positions subject to change with each new administration.
• By
The European Medicines Agency’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam.
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.